SUTENT in English translation

• SUTENT

Examples of using SUTENT in Danish and their translations into English

Behandling med Sutent bør kun indledes af læger med erfaring i behandling af GIST eller RCC.
Treatment with Sutent should only be initiated by doctors who have experience in the treatment of GIST or RCC.

Sutent gives i seksugers perioder med 50 mg dagligt i fire uger efterfulgt af to uger uden behandling.
Sutent is given in six-week cycles, with 50 mg a day for four weeks, followed by two weeks off treatment.

Med hensyn til RCC blev Sutent undersøgt hos 750 patienter, hvis cancer ikke tidligere var blevet behandlet.
In RCC, Sutent was studied in 750 patients whose cancer had not been treated before.

Sutent bør ikke anvendes til patienter, der kan være overfølsomme(allergiske) over for sunitinib
Sutent should not be used in people who may be hypersensitive(allergic)

Inlyta anven- des, når behandlingen med Sutent(sunitinib) eller"cytokiner"(en anden type kræftmedicin) har slået fejl.
Inlyta is used when treatment with Sutent(sunitinib) or'cytokines'(other anticancer medicines) has failed.

Den fuldstændige liste over de lægemidler, der kan vekselvirke med Sutent, fremgår af indlægssedlen.
See the Package Leaflet for the list of the medicines that may interact with Sutent.

Europa- Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Sutent til Pfizer Ltd den 19. juli 2006.
The European Commission granted a marketing authorisation valid throughout the European Union for Sutent to Pfizer Ltd on 19 July 2006.

Til sygdommen blev værre, var 27, 3 uger hos patienter, der fik Sutent, og 6, 4 uger hos patienter, der fik placebo.
Sutent was more effective than placebo in GIST: it took 27.3 weeks for the disease to get worse in patients who received Sutent and 6.4 weeks in patients who received placebo.

Sutent anvendes til behandling af patienter med en af følgende kræftformer:• gastrointestinal stromal tumor(GIST), en form for kræft(et sarkom) i maven og tarmene,
Sutent is used to treat patients with one of the following types of cancer:• gastrointestinal stromal tumour(GIST),

Sutent anvendes ved GIST hos patienter med svulster, der ikke kan fjernes ved operation
Sutent is used in GIST patients with tumours that cannot be removed with surgery,

Sikkerhed og effekt af SUTENT hos børn er ikke fastlagt.
The safety and efficacy of SUTENT in paediatric patients have not been established.

Følgende typer af bivirkninger er rapporteret efter markedsføring af SUTENT.
The following adverse reactions have been identified during post-approval use of SUTENT.

Patienter bør informeres om, at de kan opleve svimmelhed under behandling med SUTENT.
Patients should be advised that they may experience dizziness during treatment with SUTENT.

Tal med lægen før De tager SUTENT, hvis noget af ovennævnte gælder for Dem.
If any of those apply to you, tell you doctor before you take SUTENT.

SUTENT har vist forlængelse af QTcF- interval(Fredericas korrektion) ved ca. dobbelt terapeutisk koncentration.
At approximately twice therapeutic concentrations, SUTENT has been shown to prolong the QTcF Inteval Frederica' s Correction.

Lægen vil tale med Dem om den risiko, der er forbundet med at tage SUTENT under graviditet.
Your doctor will discuss with you the potential risk of taking SUTENT during pregnancy.

KLINISKE UNDERSØGELSER Den kliniske sikkerhed og effekt af SUTENT er undersøgt hos patienter med malign gastrointestinal stromal tumor GIST.
CLINICAL STUDIES The clinical safety and efficacy of SUTENT has been studied in the treatment of patients with malignant gastrointestinal stromal tumour(GIST) who were resistant to imatinib i. e.

Dosisjustering er ikke nødvendig, når SUTENT anvendes til patienter med mildt
No dose adjustment is recommended when administering SUTENT to patients with mild

SUTENT vil kun blive ordineret til Dem af en læge med særligt kendskab til behandling af renalcelle- kræft
SUTENT will only be prescribed to you by a doctor with experience in medicines to treat renal cell cancer

til tider fatale gastrointestinale komplikationer, herunder gastrointestinal perforation ses sjældent hos patienter med intraabdominal malignitet behandlet med SUTENT.
sometimes fatal gastrointestinal complications including gastrointestinal perforation have occurred rarely in patients with intra-abdominal malignancies treated with SUTENT.